Law360, New York (September 07, 2011, 6:47 PM ET) -- An attorney for Mylan Pharmaceuticals Inc. told a New York federal judge Wednesday that its generic version of Teva Pharmaceutical Industries Ltd.'s multiple sclerosis drug Copaxone doesn't infringe several Teva patents.
“They're different compositions, and they have different molecular ratios,” said Mylan attorney Shannon M. Bloodworth of Perkins Coie LLP in a standing-room-only courtroom in downtown Manhattan.
The remarks came during opening statements in a consolidated bench trial before U.S. District Judge Barbara S. Jones in two cases over Teva's allegations that Mylan and Novartis AG's...
Teva's Copaxone Trial Kicks Off Against Mylan, Sandoz
To view the full article, take a free trial now.
